Clinical Trial Update: Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TOL101 induction versus anti-thymocyte globulin to prevent kidney transplant rejection, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Renal Transplant

Drugs mentioned

• TOL101
• anti-thymocyte globulin (antithymocyte globulin)

Snippet

Sponsor: Tolera Therapeutics, Inc | Conditions: End Stage Renal Disease, Renal Transplant | Phase 1, Phase 2 | Status: UNKNOWN